United Health: New Hepatitis C Drug Costs Far More Than Forecast

UnitedHealth Group said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences in its first three months on the market, an amount that was “multiple” times what it had expected.
Reuters